Spruce Street Capital LP Boosts Stock Holdings in Lexeo Therapeutics, Inc. $LXEO

Spruce Street Capital LP lifted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 430.6% during the 1st quarter, HoldingsChannel reports. The fund owned 928,593 shares of the company’s stock after purchasing an additional 753,593 shares during the period. Lexeo Therapeutics accounts for 1.3% of Spruce Street Capital LP’s portfolio, making the stock its 24th biggest position. Spruce Street Capital LP’s holdings in Lexeo Therapeutics were worth $5,330,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of LXEO. Dimensional Fund Advisors LP lifted its position in shares of Lexeo Therapeutics by 27.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company’s stock valued at $6,332,000 after buying an additional 240,692 shares in the last quarter. Bleakley Financial Group LLC purchased a new stake in Lexeo Therapeutics in the 1st quarter worth $275,000. Avoro Capital Advisors LLC acquired a new position in Lexeo Therapeutics during the fourth quarter worth $32,769,000. Caitong International Asset Management Co. Ltd acquired a new position in Lexeo Therapeutics during the fourth quarter worth $37,000. Finally, Invesco Ltd. purchased a new position in Lexeo Therapeutics during the fourth quarter valued at $4,598,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Trading Down 1.1%

LXEO opened at $4.66 on Friday. The stock’s 50-day moving average price is $4.75 and its 200 day moving average price is $6.02. Lexeo Therapeutics, Inc. has a 12-month low of $3.60 and a 12-month high of $10.99. The firm has a market cap of $365.91 million, a price-to-earnings ratio of -3.21 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, research analysts forecast that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Insider Activity at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 62,204 shares of company stock valued at $280,089 over the last three months. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LXEO shares. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 10th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.